Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
12.1M
-
Shares change
-
+2.55M
-
Total reported value, excl. options
-
$171M
-
Value change
-
+$36M
-
Number of buys
-
37
-
Number of sells
-
-18
-
Price
-
$14.19
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q1 2020
74 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q1 2020.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.1M shares
of 43.4M outstanding shares and own 27.76% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.5M shares), Avoro Capital Advisors LLC (1.87M shares), BlackRock Inc. (1.33M shares), Slate Path Capital LP (871K shares), Corriente Advisors, LLC (820K shares), MANGROVE PARTNERS (601K shares), Prosight Management, LP (552K shares), STATE STREET CORP (372K shares), 683 Capital Management, LLC (320K shares), and GEODE CAPITAL MANAGEMENT, LLC (309K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.